The 36-month beta value for FATE is at 1.86. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 12 as “hold,” and 0 as “sell.”
The public float for FATE is 97.96M, and currently, shorts hold a 16.23% of that float. The average trading volume for FATE on November 26, 2024 was 1.71M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FATE) stock’s latest price update
Fate Therapeutics Inc (NASDAQ: FATE)’s stock price has increased by 5.68 compared to its previous closing price of 2.29. However, the company has seen a 6.61% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-20 that Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024.
FATE’s Market Performance
FATE’s stock has risen by 6.61% in the past week, with a monthly drop of -8.68% and a quarterly drop of -32.59%. The volatility ratio for the week is 12.44% while the volatility levels for the last 30 days are 13.14% for Fate Therapeutics Inc The simple moving average for the last 20 days is 1.11% for FATE stock, with a simple moving average of -44.56% for the last 200 days.
Analysts’ Opinion of FATE
Piper Sandler, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6, previously predicting the price at $4. The rating they have provided for FATE stocks is “Overweight” according to the report published on June 17th, 2024.
Wells Fargo gave a rating of “Equal Weight” to FATE, setting the target price at $6 in the report published on March 27th of the previous year.
FATE Trading at -17.26% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.59% of loss for the given period.
Volatility was left at 13.14%, however, over the last 30 days, the volatility rate increased by 12.44%, as shares sank -15.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.89% lower at present.
During the last 5 trading sessions, FATE rose by +6.61%, which changed the moving average for the period of 200-days by -61.53% in comparison to the 20-day moving average, which settled at $2.39. In addition, Fate Therapeutics Inc saw -35.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Xu Yuan, who sale 633 shares at the price of $4.23 back on Aug 06 ’24. After this action, Xu Yuan now owns 8,669 shares of Fate Therapeutics Inc, valued at $2,678 using the latest closing price.
Xu Yuan, the Director of Fate Therapeutics Inc, proposed sale 633 shares at $4.23 during a trade that took place back on Aug 06 ’24, which means that Xu Yuan is holding shares at $2,678 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -14.62 for the present operating margin
- -2.3 for the gross margin
The net margin for Fate Therapeutics Inc stands at -13.25. The total capital return value is set at -0.43. Equity return is now at value -46.59, with -34.32 for asset returns.
Currently, EBITDA for the company is -172.23 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 25.04. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.29.
Conclusion
In conclusion, Fate Therapeutics Inc (FATE) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
